Lantern Pharma Stock Price, News & Analysis

Lantern Pharma Inc. (NASDAQ: LTRN) is an AI-driven, clinical-stage biotechnology company focused on transforming oncology drug discovery and development. Operating in the pharmaceutical preparation manufacturing industry, Lantern uses artificial intelligence, machine learning, and genomic data to streamline the discovery, development, and potential commercialization of targeted cancer therapies. The company describes itself as an AI company transforming the cost, pace, and timeline of oncology drug discovery and development through its proprietary RADR® platform and a growing pipeline of precision oncology drug candidates.

AI-Driven Drug Discovery and RADR® Platform

At the core of Lantern Pharma’s business model is RADR®, a proprietary artificial intelligence and machine learning platform that integrates hundreds of billions of oncology-focused data points and a large library of advanced ML algorithms. According to company disclosures, RADR® is used to identify biomarkers, predict drug response, design smarter clinical trials, uncover novel therapeutic opportunities, and accelerate drug development timelines. The platform supports Lantern’s internal pipeline and is also being advanced as a set of modules and services for pharmaceutical and research partners.

Lantern reports that RADR® powers multiple AI modules, including tools for biomarker discovery, drug combination prediction, and blood–brain barrier permeability prediction. The platform has been used to help identify genomically defined patient populations, refine clinical trial designs, and support precision oncology strategies across both solid tumors and blood cancers. Lantern also highlights the use of RADR® in developing disease models, integrating multi-omic data, and guiding patient stratification and biomarker-enriched trials.

Clinical-Stage Pipeline and Precision Oncology Focus

Lantern Pharma’s clinical-stage pipeline includes several AI-advanced drug candidates designed for genomically defined cancer populations. The company states that its clinical-stage programs include LP-184, LP-284, and LP-300, with additional work in an antibody-drug conjugate (ADC) program and a central nervous system (CNS) cancer-focused subsidiary, Starlight Therapeutics.

LP-184 is described as a next-generation acylfulvene and alkylating agent that targets solid tumors with DNA damage repair (DDR) pathway deficiencies. Lantern reports that LP-184 functions as a prodrug activated by the enzyme PTGR1, which is often overexpressed in certain tumors. Once activated, LP-184 induces DNA damage in cancer cells, leading to tumor cell death, particularly in DDR-deficient cancers. The company has completed a Phase 1a dose-escalation study (NCT05933265) in advanced solid tumors, including glioblastoma multiforme (GBM), and states that the trial met all primary endpoints for safety and pharmacokinetics, established a recommended Phase 2 dose, and showed encouraging disease control in heavily pre-treated patients.

Lantern highlights that LP-184 is being advanced in multiple biomarker-guided Phase 1b/2 clinical trials or planned trials across indications such as triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) with specific genomic alterations, recurrent GBM, and advanced urothelial carcinoma. The company also notes that LP-184 has received multiple U.S. Food and Drug Administration (FDA) designations, including Fast Track Designations for TNBC and GBM, and Orphan Drug or Rare Pediatric Disease designations for malignant gliomas, pancreatic cancer, and atypical teratoid rhabdoid tumors (ATRT). Through its wholly owned subsidiary Starlight Therapeutics, Lantern is developing LP-184 as STAR-001 for CNS cancers, including pediatric brain tumors, and has reported completion of a Type C meeting with the FDA to clarify the regulatory pathway for a pediatric CNS cancer trial.

LP-284 is described as an investigational next-generation acylfulvene with a synthetic lethal mechanism targeting DNA repair deficiencies via transcription-coupled nucleotide excision repair (TC-NER). Lantern reports that LP-284 is being evaluated in a Phase 1 trial (NCT06132503) in adult patients with relapsed or refractory B-cell non-Hodgkin’s lymphomas and solid tumors. The company has disclosed early clinical data, including a complete metabolic response in a heavily pre-treated diffuse large B-cell lymphoma (DLBCL) patient who had previously failed multiple therapies, including CAR-T and bispecific antibody treatments. Lantern states that LP-284 has received multiple FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas and is being explored both as monotherapy and in combination with existing antibody-based therapies.

LP-300 is being evaluated in the Phase 2 HARMONIC™ trial for non-small cell lung cancer (NSCLC) in never-smoker patients. Lantern describes LP-300 as part of a combination regimen with standard-of-care chemotherapy in NSCLC adenocarcinoma patients who have progressed after tyrosine kinase inhibitor therapy. The company has reported clinical benefit observations, including a complete response in a never-smoker NSCLC patient treated with LP-300 plus chemotherapy, and notes that the HARMONIC™ trial has active sites in the United States and Asia, including Japan and Taiwan.

RADR®-Enabled AI Modules and Partner-Facing Platforms

Beyond its internal pipeline, Lantern Pharma emphasizes the development of commercial-ready AI modules derived from RADR®. The company has introduced platforms such as predictBBB.ai, an ensemble machine learning model for predicting blood–brain barrier permeability, and LBx-AI, an AI-powered liquid biopsy analysis platform for treatment response prediction and biomarker discovery in cancer. Lantern reports that predictBBB.ai has achieved high accuracy metrics in benchmark evaluations and can screen large numbers of molecular candidates for CNS drug development, while LBx-AI has demonstrated predictive performance in non-small cell lung cancer and can infer tumor characteristics such as PD-L1 expression from circulating tumor DNA.

Lantern has presented these platforms at scientific meetings, including the AI for Biology and Medicine symposium, and describes them as commercially deployed or production-ready resources for biopharma partners and research collaborators. The company has indicated that select RADR® modules may be made available as open-access or partner-access tools, supporting external drug discovery, biomarker research, and clinical development projects.

Global AI Center of Excellence and Expansion of RADR®

Lantern Pharma has announced plans to establish an AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India. According to the company, this center is intended to serve as a global scale-up hub for its AI platform, focusing on large-scale data engineering, development of machine learning-ready disease models, and integration with global biopharma customers and partners. The initiative is described as a phased deployment aimed at industrializing Lantern’s AI capabilities in oncology and expanding RADR® applications into additional disease areas such as inflammation, immunology, and neurodegenerative diseases through collaborations with biopharma partners.

The Bengaluru center is expected to support multi-agent AI systems for oncology, including modules for data aggregation, predictive modeling, biomarker discovery, clinical trial optimization, and molecular optimization. Lantern also notes that the center will contribute to the development of specialized large language models (LLMs) and large quantitative models (LQMs) for molecular assessment, optimization, and de novo candidate generation, as well as integration of under-represented patient populations and real-world clinical data into its AI frameworks.

Regulatory and Corporate Profile

Lantern Pharma Inc. is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol LTRN. The company describes itself as an emerging growth company under applicable U.S. securities regulations. SEC filings indicate that Lantern holds annual stockholder meetings, maintains an equity incentive plan, and uses at-the-market (ATM) offerings as one mechanism for raising capital. The company has also amended its bylaws to adjust quorum requirements for stockholder meetings and has reported on board appointments and governance matters in its current reports on Form 8-K and proxy statements.

Through its combination of AI-enabled platforms, clinical-stage oncology programs, and collaborations with academic and biopharma partners, Lantern Pharma positions itself as an AI-driven oncology company focused on precision medicine and data-guided therapeutic development. Investors and researchers reviewing LTRN typically examine the progress of its clinical trials, the performance and adoption of its RADR®-based AI modules, its regulatory designations, and its partnership activities with pharmaceutical companies and research institutions.